Vanqua raises $45M; Aerovate to look for strategic alternatives
Plus, news about GSK, iTeos, Oxolife and SmallCella: Vanqua Bio reels in $45M: The Chicago neuroscience biotech extended its Series B, a spokesperson confirmed to Endpoints News. The company originally...
View ArticleClik here to view.
Gene insertion startup Komo Biosciences launches with new integrase...
Scientists at the University of Hawaii have improved tools for making large changes to genomes and have licensed the technology to a new startup called Komo Biosciences, its leaders told Endpoints News...
View ArticleClik here to view.
HilleVax's stock tumbles after Phase 2b norovirus vaccine fails in infants
Takeda spinout HilleVax’s stock $HLVX sunk over 85% on Monday morning after the company announced its norovirus vaccine candidate failed a mid-stage trial in infants. While the vaccine, dubbed HIL-214,...
View ArticleInfections are major cause of non-relapse deaths after CAR-T cell therapy,...
A meta-analysis of CAR-T cell therapy studies found that just over half of cancer patient deaths that are not because of relapse are due to infections. “The main takeaway as clinicians is infections,...
View ArticleClik here to view.
Digital health deals rallied in the first half of 2024, though funding still...
Digital health startups raised $5.7 billion in the first half of 2024, slightly less than the $6.1 billion in the same period in 2023, according to venture and advisory firm Rock Health. But more...
View ArticleWhen can pharma companies correct online misinformation? FDA explains
The FDA on Monday laid out its latest expectations for how pharma companies can correct misinformation spreading online about their medical products. The draft guidance, which comes in the form of a...
View ArticleLilly bests Novo Nordisk in observational study of GLP-1 drugs
Patients receiving Eli Lilly’s diabetes medicine Mounjaro were “significantly more likely” to achieve clinically meaningful weight loss compared to those on Novo Nordisk’s Ozempic, according to a new...
View ArticleGilead's HIV drug patent battle with CDC continues with government appeal
The US government is appealing a jury’s decision that granted Gilead a major win in a patent fight over the company’s blockbuster HIV treatments Truvada and Descovy. Lawyers for the government last...
View ArticleRoche to reintroduce ocular implant two years after pulling it off the market
Roche plans to reintroduce Susvimo, its ocular implant pulled almost two years ago for manufacturing issues, in the coming weeks. In late 2022, the company’s Genentech unit withdrew the implant after a...
View ArticleAcquired biotech accuses Novartis of letting IL-15 asset 'wither on the vine'
Novartis is being accused of deliberately stalling the development of an acquired IL-15 asset, costing a smaller biotech up to $940 million in milestone payments plus additional damages and costs. The...
View ArticleClik here to view.
SciRhom secures €63M Series A for autoimmune disease program
SciRhom has clinched €63 million ($70 million) in a Series A raise to advance its lead monoclonal antibody program through a first-in-human trial set to start in the second half of the year. The Phase...
View ArticleBiovance debuts with €51M to lift up biotech scene in Portugal and southern...
Nearly a decade ago, Ricardo Perdigão Henriques’ colleagues balked at the idea of him leaving Boston to return home to Portugal to build a biotech ecosystem as a VC. “They said, ‘You’re crazy, Ricardo....
View ArticleExclusive: Courier Health raises $16.5M Series A to help biopharma companies...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) As more specialty drugs hit the market, a startup just raised fresh funding to help biopharma companies...
View ArticleHouse speaker plans vote on Biosecure Act as part of China legislation push
House Speaker Mike Johnson (R-LA) on Monday pledged a vote this year on a bill targeting Chinese biotech contractors, providing fresh momentum to the legislation. Johnson listed the Biosecure Act among...
View ArticleClik here to view.
Pfizer CSO Mikael Dolsten to depart after 15 years leading drug giant's R&D
Mikael Dolsten, a longtime leader of drug R&D at one of the world’s biggest pharma giants, will depart his post as chief scientific officer at Pfizer, the company said Tuesday morning. The 15-year...
View ArticleFTC says PBMs ‘exercise vast control’ over healthcare in long-awaited report...
Federal antitrust regulators issued a report describing the PBM industry as highly concentrated among a handful of companies that use their market power to put pressure on clients and competitors, and...
View ArticleClik here to view.
Chinese drugmakers still lag in R&D depth despite outpacing Europeans in new...
China may have outranked Europe for the first time in the number of new medicines it developed through to launch last year. But analysts told Endpoints News that Europe still has the edge when it comes...
View ArticleClik here to view.
Biopharma’s 20 highest-paid CEOs of 2023, earning $20M+ pay packages
The best-paid CEOs of 2023 fall largely into two groups: They’re either running some of the world’s biggest drugmakers, or they were given huge incentive packages in their first year on the job or as...
View ArticleKymera's stock rises after derma investigation expands; Ligand buys Apeiron
Plus, news about AEON Biopharma, Moderna and Mitsubishi Tanabe: Sanofi expands dermatology trials: Kymera Therapeutics said that expanding the Phase 2 hidradenitis suppurativa and atopic dermatitis...
View ArticleClik here to view.
UniQure trumpets mid-stage data for Huntington's disease gene therapy
UniQure on Tuesday released new two-year data on its Huntington’s disease gene therapy called AMT-130, sending its stock $QURE up by more than 50%. Interim results from the Phase 1/2 trials showed nine...
View Article